NEXIUM Drug Patent Profile

Which patents cover Nexium, and what generic alternatives are available?

Nexium is a drug marketed by Astrazeneca and Astrazeneca Lp and is included in six NDAs.

The generic ingredient in NEXIUM is esomeprazole sodium. There are seventy-four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the esomeprazole sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nexium

A generic version of NEXIUM was approved as esomeprazole sodium by DEVA HOLDING AS on March 6^th, 2017.

Summary for NEXIUM

US Patents:	0
Applicants:	2
NDAs:	6
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NEXIUM

Paragraph IV (Patent) Challenges for NEXIUM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NEXIUM	Delayed-release for Oral Suspension	esomeprazole magnesium	2.5 mg and 5 mg	021957	1	2018-09-24
NEXIUM	Delayed-release for Oral Suspension	esomeprazole magnesium	10 mg	022101	1	2018-07-06
NEXIUM	Delayed-release for Oral Suspension	esomeprazole magnesium	20 mg and 40 mg	021957	1	2013-08-01
NEXIUM	Delayed-release Capsules	esomeprazole magnesium	20 mg and 40 mg	021153	1	2005-08-05

US Patents and Regulatory Information for NEXIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	NEXIUM	esomeprazole magnesium	CAPSULE, DELAYED REL PELLETS;ORAL	021153-001	Feb 20, 2001	AB	RX	Yes	No
Astrazeneca	NEXIUM	esomeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	021957-002	Oct 20, 2006	AB	RX	Yes	Yes
Astrazeneca	NEXIUM	esomeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	021957-004	Dec 15, 2011	AB	RX	Yes	No
Astrazeneca Lp	NEXIUM 24HR	esomeprazole magnesium	CAPSULE, DELAYED RELEASE;ORAL	204655-001	Mar 28, 2014		OTC	Yes	Yes
Astrazeneca	NEXIUM	esomeprazole magnesium	CAPSULE, DELAYED REL PELLETS;ORAL	021153-002	Feb 20, 2001	AB	RX	Yes	Yes

International Patents for NEXIUM

See the table below for patents covering NEXIUM around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2003516985
Estonia	03149	Sünergiline kombinatsioon maohappe sekretsiooni inhibeerivast ainest ja happetundlikust antibiootikumist, protsess selle valmistamiseks ja seda sisaldav ravimpreparaat
Croatia	P920855	PHARMACEUTICAL FORMULATIONS OF ACID LABILE SUBSTANCES FOR ORAL USE
China	1126993
European Patent Office	0496437	Utilisation d'un matériau à noyau spécifique et à couches pour obtenir des formulations pharmaceutiques stables pour la coloration de l'omeprazole (Use of specific core material and layers to obtain pharmaceutical formulations stable to discolouration of omeprazole)

Supplementary Protection Certificates for NEXIUM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1020461	300482	Netherlands		PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMZOUT; NATIONAL REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: GB PL 17091/0263 - 0001 20101105
0984957	PA2011005	Lithuania		PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
1020461	C300482	Netherlands		PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMZOUT; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17091/0263 - 0001 20101105
0984957	PA2011005,C0984957	Lithuania		PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
1411900	SPC/GB11/015	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105

Investment Scenario, Market Dynamics, and Financial Trajectory for NEXIUM

Last updated: February 3, 2026

Executive Summary

NEXIUM (esomeprazole magnesium) is a proton pump inhibitor (PPI) indicated primarily for gastroesophageal reflux disease (GERD), erosive esophagitis, and related gastric acid-related disorders. Originally branded by AstraZeneca, NEXIUM carved a significant share in the proton pump inhibitor market, transforming from a blockbuster drug into a complex generic market landscape. This report provides an in-depth analysis of NEXIUM’s current investment scenario, market dynamics, and projected financial trajectory, considering patent expirations, competitive pressures, regulatory factors, and emerging therapeutic alternatives.

---

1. Overview of NEXIUM's Market Position and Historical Financial Performance

1.1. Origin and Market Launch

• Launch Date: 2001 (United States by AstraZeneca)
• Initial FDA Approval: 2001
• Indications: GERD, erosive esophagitis, Zollinger-Ellison syndrome
• Peak Sales: $6.2 billion globally in 2014 (AstraZeneca)

1.2. Revenue Trends Over Time

Year	Revenue (USD Million)	Notes
2012	$4,600	Before patent expiry
2013	$4,220	Patent expiry imminent
2014	$6,200	Peak global revenue
2015	$2,020	Post-generic entry
2016	$1,665	Continued generics impact
2020	$900	Market share erosion ongoing

Key Observations:

• NEXIUM experienced rapid revenue decline post patent expiry due to the entrance of generic competitors.
• Despite sales erosion, NEXIUM retained clinical relevance, especially in hospitals and niche markets.

---

2. Patent and Regulatory Landscape

2.1. Patent Status and Expiry

Patent Type	Original Expiration	Extended/Additional Patents	Last Patent Expiry Date
Composition of Matter	2011	2014 (with extension)	2014
Method-of-Use	Various, expired by 2014	N/A	—
Formulation Patents	Extended up to 2014	N/A	—

Implication:
Generic competition proliferated post-2014, leading to market erosion.

2.2. Regulatory Approvals

• FDA: Approved for multiple indications; generic versions approved starting 2014.
• Healthcare Regulations: Patent cliff activated, prompting increased generics; regulatory barriers shifted focus to biosimilars and novel formulations.

---

3. Market Dynamics

3.1. Competitive Landscape

Competitors	Product Names	Market Share (2022)	Key Differentiator
Brand	NEXIUM (AstraZeneca)	<5%	Brand loyalty, hospital use
Generics	Multiple (e.g., esomeprazole, omeprazole)	85-90% combined	Lower cost, wider access
Newer Drugs	Vonoprazan (Japan), Acid Blockers	Growing in select markets	Different mechanism, longer-lasting effects

3.2. Price Erosion & Market Share Trends

• Post-generic entry:
  • Price reductions of 70-80%
  • Market share predominantly captured by generics
• Hospital & OTC Segments:
  • Slower decline; some branded use persists for resistant cases
• Emerging Markets:
  • Growing demand for affordable generics

3.3. Clinical and Therapeutic Trends

• Shift towards H2-receptor antagonists and novel acid suppression agents.
• Increased focus on PPI-associated risks (e.g., KDIGO guidelines) affecting prescribing behaviors.

---

4. Investment Scenarios

4.1. Once-Patent-Exclusive Scenario

• Limited to brand for niche markets (specialty hospitals, resistant cases).
• Revenue potential: declining, with a risk of obsolescence.

4.2. Post-Patent-Expiry Generic Market

• Revenue primarily from biosimilar and generic sales.
• Margins compressed; volume-driven growth models dominate.

4.3. Niche or Value-Added Formulations

• Opportunities in extended-release formulations or combination therapies.
• Rising interest in personalized medicine and tailored drug delivery systems.

4.4. Strategic Licensing and Partnerships

• Licensing NEXIUM's patents or formulations for emerging markets.
• Joint development with biotech firms for new indications.

---

5. Financial Trajectory Outlook

Parameter	2022	2025 (Forecast)	2030 (Forecast)
Revenue	$900M	$350M	<$100M
Market Share	2-3% (post-generic erosion)	Diminishing	Negligible
Gross Margin	~80% (brand)	~60-65% (generics)	Lower
R&D Investment	Minimal	Focused on niche areas	Low or exit

5.1. Revenue Drivers

• Volume of specialized use cases
• Geographic expansion in emerging markets
• Biosimilar and generic competition

5.2. Cost Structure and Margins

• Reduced R&D costs due to patent expiration
• Focus on manufacturing efficiency and supply chain optimization

5.3. Investment Risks

• Regulatory hurdles for new formulations
• Market shifts towards alternative treatments
• Price compression from intense generic competition

---

6. Comparative Analysis: NEXIUM vs Alternative Therapies

Therapy Type	Example Drugs	Key Features	Market Penetration	Advantages	Limitations
Proton Pump Inhibitors	Omeprazole, Pantoprazole	Cost-effective, broad use	Dominant	Well-understood safety	Long-term risks, resistance
Novel Agents	Vonoprazan	Longer action, fewer side-effects	Growing	Potential replacement	Limited approval outside Japan
H2 Blockers	Ranitidine, Famotidine	Cheaper, OTC	Significant	Lower cost	Less effective for severe cases

---

7. Regulatory and Policy Framework Impact

• Pricing & Reimbursement: Increasing pressure for generic adoption reduces profitability.
• Patent Litigation & Strategies: Companies may pursue patent extensions or litigation to delay generic entry.
• Healthcare Policies: Move towards cost containment affects drug pricing and market growth.

---

8. Key Investment Considerations

• Market Saturation Post-Patent: Significant revenue decline expected, emphasizing the importance of niche markets.
• Generic Competition: Dominates, compressing margins; innovation is limited.
• Emerging Opportunities: Biosimilars, personalized medicine, reformulation.
• Geographic Expansion: Focus on emerging markets for continued revenues.
• Regulatory Risks: Patent challenges, approval delays, and evolving safety standards.

---

9. Key Takeaways

• NEXIUM's peak revenue has largely been realized; future growth relies on niche applications or repositioning.
• The patent expiry in 2014 catalyzed erosion, with generics now representing the bulk market share.
• Investment strategies should consider diversification into formulations, biosimilars, and emerging markets.
• Competition from newer agents, combined with safety concerns related to long-term PPI use, influence prescribing patterns.
• A cautious outlook persists unless innovative formulations or indications extend NEXIUM's lifecycle.

---

10. FAQs

Q1: What are the main factors influencing NEXIUM’s declining sales?
Patent expiration, generic entry, price erosion, and the shift towards alternative therapies have significantly reduced NEXIUM's revenues.

Q2: Are there any opportunities for NEXIUM in emerging markets?
Yes, increased demand for affordable PPIs and expanding healthcare infrastructure provide growth prospects, contingent on regulatory approvals.

Q3: How do biosimilars impact NEXIUM’s future?
While biosimilars mainly target biologics, the trend towards lower-cost generic PPIs affects NEXIUM's market share, necessitating adaptation.

Q4: Can NEXIUM be repositioned for new indications?
Repositioning opportunities are limited; development of new indications faces regulatory hurdles and clinical validation challenges.

Q5: What is the outlook for NEXIUM’s profitability in the next decade?
Profitability will decline sharply unless strategic moves into niche formulations, licensing, or adjunctive markets are successful.

---

References

[1] AstraZeneca Annual Reports 2012-2020.
[2] IQVIA, Global Medicine Market Reports 2022.
[3] U.S. FDA Drug Approvals Database, 2001-2022.
[4] Reuters Pharmaceutical Data, 2022.
[5] MarketWatch, Proton Pump Inhibitors Market Analysis, 2022.